Cognitive Decline and Dementia in Diabetes
Saturday, June 26, at 8:30 a.m. ET
Q&A with Florin Despa, PhD
What is your presentation about?
I will summarize case-control studies and laboratory data with a focus on diabetes-related amylin dysregulation in the setting of dementia. These studies point to amyloid-forming amylin secreted by the pancreas as a potential missing molecular link between metabolic disorders such as type 2 diabetes and increased risk for brain microvascular and Alzheimer’s pathologies. Specifically, amylin dysregulation contributes to both type 2 diabetes and Alzheimer’s disease.
What makes this topic important in 2021?
Approximately 34 million American adults have diabetes and more than 5 million Americans have Alzheimer’s disease; many persons with cognitive decline suffer from diabetes. Associations between antidiabetic medication and dementia are not uniformly in the direction of increased protection, suggesting a limited knowledge on the mechanisms linking type 2 diabetes to the Alzheimer’s clinical syndrome.
Which subset of attendees shouldn’t miss this presentation?
Clinicians and basic science scientists interested in brain health and cognitive impairment in the diabetic population should attend this presentation. Pharmaceutical companies working on drug development to keep the brain healthy in persons with diabetes or prediabetes are also encouraged to attend this talk.
What else should Scientific Sessions attendees know about your presentation?
Because prediabetic insulin resistance is characterized by hypersecretion of amylin, lowering the blood level of amylin should protect against the development of brain microvascular and Alzheimer’s pathologies. In my talk, I will present data supporting this hypothesis.